Avastin Is Denied for Breast-Cancer Patients! Obamacare's "Death Panels" Kick In!

"Avastin" is a drug that was prescribed for colon cancer and in 2008, approved by the FDA for late-stage breast cancer. About 17,500 women in the U.S. benefit from the drug at a cost of about $8,000 per month.

Preliminary studies found that the drug aided in preventing the worsening of the disease, while two newer studies found it had little effect.

But here's the issue: The FDA advisory board voted 12-1 to stop its endorsement of this treatment for breast cancer NOT because of its effectiveness--but because of its cost effectiveness!

If the FDA revokes its approval of "Avastin" U.S. insurers will stop paying for the drug (for women who are suffering from breast cancer)!

The story was published in the UK Telegraph.

UPDATE: The FDA has revoked Avastin Approval for Breast Cancer

The recommendation by the FDA Advisory Board has lead to the controversy that Obamacare would deny treatment to those already receiving care, as with "Avastin". The critics maintain that it is drug rationing in a life-and-death situation and is the equivalent of a "death panel".

Well, it's happened and it is!

The fact that the FDA is approving this drug for lung, colon, kidney and brain cancer but retracting its endorsement for late-stage breast cancer says volumes!

What about the poor women who are taking this drug and seeing the benefit??? What will they do after September 17th, if the FDA revokes its approval?

The FDA Advisory Board has admitted that they dropped their endorsement of "Avastin" because of COST EFFECTIVENESS, not because of the effectiveness of the drug!

Did you write our congressmen and women and our senators to protest!?

NOTE: Read the entire article: http://www.telegraph.co.uk/health/healthnews/7948878/US-breast-cancer-drug-decision-marks-start-of-death-panels.html